UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12B-25
NOTIFICATION OF LATE FILING
Commission File Number 0-51931
(Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q
[ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR
FOR PERIOD ENDED: March 31, 2007
--------------
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
FOR THE TRANSITION PERIOD ENDED:
Read Attached Instruction Sheet Before Preparing Form. Please Print or Type.
NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS
VERIFIED ANY INFORMATION CONTAINED HEREIN.
If the notification relates to a portion of the filing checked above, identify
the item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
Stem Cell Therapy International, Inc
------------------------------------
Full Name of Registrant
------------------------------------
Former Name if Applicable
2203 N. Lois Avenue, 9th Floor
------------------------------------
Address of Principal Executive Offices (Street and Number)
Tampa, FL 33607
------------------------------------
City, State and Zip Code
PART II - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25 (b), the following
should be completed. (Check appropriate box)
| (a) The reasons described in reasonable detail in Part III of this form
| could not be eliminated without unreasonable effort or expense;
| --------------------------------------------------------------------------
| (b) The subject annual report, semi-annual report, transition report on
| Form 10-K, 10-KSB, 20-F, 11-K or Form N-SAR, or portion thereof
| will be filed on or before the 15th calendar day following the prescribed
[x]| due date; or the subject quarterly report or transition report on Form 10-
| Q, 10-QSB, or portion thereof will be filed on or before the fifth
| calendar day following the prescribed due date; and
| --------------------------------------------------------------------------
| (c) The accountant's statement or other exhibit required by Rule 12b-
| 25(c) has been attached if applicable.
| --------------------------------------------------------------------------
1
PART III
NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 10-KSB, 11-K. 20-F,
10-Q, 10-QSB, N-SAR, or the transition report or portion thereof could not be
filed within the prescribed time period. (Attach extra sheets if needed.)
The registrant has experienced delays in completing its financial statements for
the year ended March 31, 2007 as the registrant's auditor has not had
sufficient time to conduct a review. As a result, the registrant is delayed in
filing its Form 10-K for the year ended March 31, 2007
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
M. Richard Cutler 706 737-6600
----------------- --------- ----------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is
no, identify report(s). [X] Yes [ ] No
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof? [ ] Yes [X] No
If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
STEM CELL THERAPY INTERNATIONAL, INC.
-------------------------------------
(Name of Registrant as specified in charter)
Has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date June 29, 2007 By: /s/ Calvin Cao
--------------------- -----------------------------------
Calvin Cao, Chief Executive Officer
2